智通财经APP讯，思路迪医药股份(01244)发布公告，国家药品监督管理局(NMPA)已正式受理公司商业化产品恩维达® (通用名：恩沃利单抗注射液，原研代号：KN035)联合吉西他滨和奥沙利铂(GEMOX)方案，用于一线治疗不可切除或转移性胆道癌 (BTC)的新药上市申请(NDA)。此次受理基于III期临床试验(KN035-CN-005)的临床研究结果，这是一项针对中国晚期一线胆道癌患者设计的随机、平行对照、多中心III期临床试验，旨在评估恩维达®(KN035)联合GEMOX方案对比单纯GEMOX方案的疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.